FGFR2 and neoplasm: Patients harbouring tumours with KRAS, TP53 and/or SMAD4 mutations had worse overall survival and lower recurrence-free survival after surgery compared to those with FGFR2-fusions, IDH mutations, BAP1 mutations or none of these genetic alterations.93